Royalty Pharma to announce Q2 2026 financial results on August 5
Royalty Pharma plc is set to release its Q2 2026 financial results on August 5, 2026, prior to market open. A conference call and webcast are scheduled for 8:00 a.m. ET to review the quarterly performance. The company, established in 1996, holds royalties on over 35 commercial products and funds biopharmaceutical innovation.
*this image is generated using AI for illustrative purposes only.
Royalty Pharma plc will announce its second quarter 2026 financial results on Wednesday, August 5, 2026, before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time the same day to discuss the performance. Investors can access the live webcast and conference call details through the "Investors" section of the Royalty Pharma website. A replay of the call will be archived on the website for at least 30 days following the event.
Conference Call Details
| Event | Date | Time |
|---|---|---|
| Financial Results Release | August 5, 2026 | Before U.S. markets open |
| Conference Call & Webcast | August 5, 2026 | 8:00 a.m. ET |
About Royalty Pharma plc
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. The company collaborates with innovators ranging from academic institutions and non-profits to global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties entitling it to payments based on the top-line sales of leading therapies. Its current portfolio includes royalties on more than 35 commercial products, such as Vertex’s Trikafta and Alyftrek, GSK’s Trelegy, and Roche’s Evrysdi, alongside 19 development-stage product candidates.
How might the performance of key therapies like Trikafta and Trelegy impact Royalty Pharma's Q2 2026 financial results?
What new developments or milestones are expected from the 19 development-stage product candidates in the company's portfolio?
Could Royalty Pharma announce any new royalty acquisitions or partnerships during the Q2 2026 earnings call?
19
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
